This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

HomeHomeVaccines HomepageLoadingDisease AreasDisease AreasPneumococcal diseaseTick-borne encephalitis (TBE)Meningococcal diseaseDisease Areas

Menu

Close

Our BrandsOur BrandsApexxnar®Nimenrix®Trumenba®Prevenar 13®TicoVac®Vaccine TechnologiesVaccine TechnologiesConjugate TechnologyPolysaccharide VaccinesInactivated VaccinesSupport & ResourcesSupport & ResourcesClinic support materials

Prescribing Information and information on adverse event reporting can be found at the bottom of the page.

Conjugate Technology

Conjugate vaccines are a type of subunit vaccine, which are made from components of a pathogen, incapable of causing disease but specifically selected to help stimulate an immune response.1 Other examples of subunit vaccines also include polysaccharide vaccines and protein-based vaccines.


When a polysaccharide is attached, or conjugated, to something else, a stronger immune response can be generated than with just the polysaccharide2, this is known as a conjugate vaccine. In a conjugate vaccine, the polysaccharide component is attached to a protein to help the immune system recognise and respond to the sugar on the bacteria.3

Why vaccinate with a Conjugate Vaccine?

In a conjugate vaccine, the polysaccharide antigens are conjugated to a carrier protein3 which enables the antigens to be delivered to cells that they would not be able to access without the protein.3 Once these antigens are taken up and presented, an immune response is initiated. 

The immune response to a conjugate vaccine is more favourable than without the conjugate protein as the conjugated carrier protein induces a T cell-dependent response, which facilitates the production of memory B cells.4

This generation of memory B cells elicits immune memory, which supports a booster response to re-exposure to pathogens, such as pneumococcal bacteria. Therefore the production of new memory B cells in response to conjugate vaccines may provide long term immunity.4,5

Pfizer's Conjugate Vaccines


Pfizer currently offers three conjugate vaccines.

Two are polysaccharide conjugate vaccines for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae 6,7APEXXNAR®(pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) for adults & Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) from 6 weeks.

The other is a conjugate meningococcal vaccine for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y: Nimenrix® (meningococcal Groups A, C, W-135 and Y conjugate vaccine) from 6 weeks.

APEXXNAR® (20 valent, adsorbed) is built on the foundation of Prevenar 13® (13-valent, adsorbed), adding 7 serotypes to Prevenar 13 to deliver the most serotypes in a pneumococcal conjugate vaccine.6,7 Visit our brand pages to find out more about these vaccines.

 

Explore Apexxnar Loading Get to know Prevenar 13LoadingMore on NimenrixLoading Order Clinic Materials

Help your customers to feel confident about vaccination - access MedISA to order printed clinic support materials to your surgery, pharmacy or other healthcare centre.

Order materials nowLoading
Register to receive personalised marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

Sign up hereLoading

Prescribing Information

APEXXNAR® (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed))
Prevenar 13 (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed))
Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine)

References:

1. GAVI. What are protein subunit vaccines and how could they be used against COVID-19? Last accessed April 2023.
2. Oxford Vaccine Group. Vaccine Knowledge Project. Types of vaccine. Last accessed April 2023
3. GAVI. Making strides with polysaccharides: life-saving conjugate vaccines, explained. Last accessed April 2023.
4. Pollard AJ, Perrett KP, and Beverley PC. Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nature Reviews Immunology. 2009;9:213-220.
5. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017 Dec 5;12:3457-3468. doi: 10.2147/COPD S140378. PMID: 29255353; PMCID: PMC5723118. 
6. APEXXNAR GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13461. Last accessed April 2023.
7. Prevenar 13 GB (Pneumococcal polysaccharide conjugate vaccine). Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/22689. Last accessed April 2023.
8. Nimenrix. Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/4118. L
ast accessed April 2023.​​​
References:
  1. Public Health England. The Green Book [published 2013; updated 2020]. Chapter 25: Pneumococcal. Available at https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25 Last accessed: May 2022
  2. UPDATE REFERENCES
PP-UNP-GBR-4046. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​